Beverly Hills Private Wealth LLC lifted its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 67.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,858 shares of the company’s stock after purchasing an additional 1,153 shares during the period. Beverly Hills Private Wealth LLC’s holdings in Eli Lilly and Company were worth $1,285,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in the stock. Guyasuta Investment Advisors Inc. grew its stake in Eli Lilly and Company by 4.6% in the 2nd quarter. Guyasuta Investment Advisors Inc. now owns 3,024 shares of the company’s stock worth $1,418,000 after acquiring an additional 132 shares in the last quarter. Banco Bilbao Vizcaya Argentaria S.A. grew its stake in Eli Lilly and Company by 4.8% in the first quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 82,966 shares of the company’s stock worth $28,449,000 after purchasing an additional 3,768 shares in the last quarter. Baystate Wealth Management LLC raised its position in Eli Lilly and Company by 688.2% during the 2nd quarter. Baystate Wealth Management LLC now owns 3,736 shares of the company’s stock valued at $1,752,000 after purchasing an additional 3,262 shares in the last quarter. Simon Quick Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 13.0% in the 2nd quarter. Simon Quick Advisors LLC now owns 1,874 shares of the company’s stock worth $879,000 after buying an additional 215 shares during the period. Finally, Martin Capital Partners LLC bought a new position in shares of Eli Lilly and Company during the 2nd quarter worth $234,000. Hedge funds and other institutional investors own 81.38% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on LLY shares. BMO Capital Markets raised their price target on Eli Lilly and Company from $565.00 to $633.00 and gave the company an “outperform” rating in a research note on Wednesday, August 9th. Credit Suisse Group boosted their price target on shares of Eli Lilly and Company from $490.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, August 9th. Royal Bank of Canada increased their price objective on shares of Eli Lilly and Company from $490.00 to $580.00 and gave the company an “outperform” rating in a research note on Tuesday, August 8th. Jefferies Financial Group raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $408.00 to $615.00 in a research note on Tuesday, August 8th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and twenty have issued a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $557.00.
Check Out Our Latest Research Report on Eli Lilly and Company
Insider Buying and Selling
In related news, CAO Donald A. Zakrowski sold 670 shares of the stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $571.10, for a total value of $382,637.00. Following the transaction, the chief accounting officer now owns 4,708 shares in the company, valued at approximately $2,688,738.80. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, major shareholder Lilly Endowment Inc sold 215,000 shares of the company’s stock in a transaction dated Wednesday, October 11th. The stock was sold at an average price of $605.44, for a total value of $130,169,600.00. Following the sale, the insider now owns 99,768,810 shares in the company, valued at $60,404,028,326.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Donald A. Zakrowski sold 670 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $571.10, for a total value of $382,637.00. Following the transaction, the chief accounting officer now owns 4,708 shares of the company’s stock, valued at $2,688,738.80. The disclosure for this sale can be found here. Insiders sold 536,138 shares of company stock valued at $20,881,627,358 over the last quarter. 0.13% of the stock is currently owned by company insiders.
Eli Lilly and Company Stock Performance
Shares of LLY stock opened at $610.94 on Wednesday. The business has a fifty day moving average of $576.99 and a 200 day moving average of $506.23. Eli Lilly and Company has a 1 year low of $309.20 and a 1 year high of $629.97. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.05 and a quick ratio of 0.82. The firm has a market capitalization of $579.97 billion, a price-to-earnings ratio of 110.68, a price-to-earnings-growth ratio of 3.72 and a beta of 0.33.
Eli Lilly and Company Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 0.74%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and Company’s payout ratio is 81.88%.
Eli Lilly and Company Company Profile
(Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Read More
Receive News & Ratings for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.
